Sibutramine in the treatment of obesity in women

Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/489

Full metadata record

DC Field	Value	Language
dc.contributor.author	Sadikova Nigora Gayratovna, Nazhmutdinova Diloram Kamariddinovna, Urunbaeva Diloram Anvarovna, Inoyatova Iroda Shakirovna	-
dc.date.accessioned	2020-03-03T06:45:21Z	-
dc.date.available	2020-03-03T06:45:21Z	-
dc.date.issued	2019	-
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/489	-
dc.description.abstract	We studied 30 obese women aged 43.5±3.2 years. All patients, depending on the received therapy, were divided into two groups: 1 group consisted of 15 patients receiving sibutramine, 2 group consisted of women receiving sibutramine and Metformin. All women were measured weight, height, then calculated body mass index, waist (W) and hip (H), also fasting blood sugar and 2 hours after eating, lipid spectrum, to eliminate hypothyroidism hormones TSH, free T3, free T4, antibodies to TPO. During the treatment of sibutramine with Metformin in combination led to a decrease in body weight in 15% of patients, sibutramine monotherapy was observed in 10%.	en_US
dc.language.iso	other	en_US
dc.publisher	Tashkent	en_US
dc.subject	Keywords: obesity, body mass index, sibutramine, total cholesterol, triglycerides	en_US
dc.title	Sibutramine in the treatment of obesity in women	en_US
dc.type	Article	en_US
Appears in Collections:	Thesis, Articles

Files in This Item:

File	Description	Size	Format
28..pdf	Sibutramine in the treatment of obesity in women	9.07 MB	Adobe PDF	View/Open
28..pdf	Sibutramine in the treatment of obesity in women	9.07 MB	Adobe PDF	View/Open

DSpace JSPUI